The tweet was deleted by the author.
But we saved everything 🙂.
Allogene Therapeutics has announced it will hold its first quarter 2026 conference call on Wednesday, May 13 at 2:00 p.m. Pacific Time, equivalent to 5:00 p.m. Eastern Time.
The session is expected to include updates on the company’s CAR-T and cell therapy pipeline. Investors and stakeholders can learn more about participation and details through the company’s official channels.
Allogene recently launched ALLO-329, a new allogeneic CAR-T cell therapy targeting autoimmune diseases with Dagger technology, as detailed here. The company’s CTO, Ben Beneski, participated in an industry panel on advancing next-generation cell-based therapies at a leading event earlier this year. These initiatives highlight continued activity around cell therapy development.